The combinations include EGFR inhibitor, IGF1-R/IR inhibitor, Akt inhibitor, and mTOR inhibitor that can directly or indirectly target different components of the PI3K/Akt/mTOR pathway (Fig 12) a crucial signaling cascade in several cancers [78–80]. The gene discussed is AKT1; the disease is cancer.